Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations
March 17, 2010 - … --------------------- ------------- -------- --------- STRATTERA CAP 10MG X 30 BOTL AM 00002-3227-30 A621189A … ----------------------- ------------- -------- --------- STRATTERA CAP 25MG X 30 BOTL AM 00002-3228-30 A678353A … ----------------------- ------------- -------- --------- STRATTERA CAP 60MG X 30 BOTL AM 00002-3239-30 A621202A …
Lilly Delivers Sixth Consecutive Quarter of Double-Digit Sales Growth
July 22, 2004 - … primarily by increased worldwide sales of Zyprexa ® , Strattera ® , Evista ® , Forteo ® , and Gemzar ® . Newer products-Alimta ® , Cialis ® , Forteo ® , Strattera, Symbyax ™ and Xigris ® - contributed $350.4 … primarily by increased worldwide sales of Zyprexa ® , Strattera ® , Evista ® , Forteo ® , and Gemzar ® . Newer …
Lilly Reports $.73 EPS and 10 Percent Sales Growth in the Third Quarter
October 20, 2005 - … ® (non-joint-venture sales), Cymbalta ® , Forteo ® , Strattera ® , Symbyax ® , Xigris ® and Yentreve ® -- … 6% 770.8 755.4 2% Cymbalta 182.8 32.5 N/M 450.9 32.5 N/M Strattera 140.9 163.6 (14%) 384.1 483.3 (21%) Alimta 122.3 … * Lilly announced an important update to the Strattera label, communicating new information regarding …
Lilly Reports Q1 EPS of $.77, or 13% Growth
April 20, 2006 - … -- Alimta ® , Byetta ® , Cialis ® , Cymbalta, Forteo ® , Strattera ® , Symbyax ® , Xigris ® and Yentreve ® -- … 11% Evista(R) 241.6 248.9 (3%) Cymbalta 233.3 106.8 118% Strattera 152.2 119.8 27% Alimta 130.1 93.9 39% Forteo 127.1 … $27.4 million, reflecting recent international launches. Strattera Strattera, the only nonstimulant medicine approved …
Lilly Announces 2006 Adjusted EPS of $3.18 Excluding Charges and Reported EPS of $2.45
January 31, 2007 - … Alimta(R), Byetta(R), Cialis(R), Cymbalta(R), Forteo(R), Strattera(R), Symbyax(R), Xigris(R) and Yentreve(R) -- … 26% 611.8 463.2 32% Forteo 172.1 118.0 46% 594.3 389.3 53% Strattera 156.3 168.0 (7)% 579.0 552.1 5% Significant Events … inventory levels for certain products (primarily Strattera, Prozac(R), and Gemzar) that reduced 2005 sales by …
Lilly Reports $.68 Earnings Per Share in the First Quarter
April 18, 2005 - … ® (non-joint-venture sales), Cymbalta ® , Forteo ® , Strattera ® , Symbyax ® , Xigris ® and Yentreve ® -- … 681.1 6% Gemzar(R) 304.6 279.0 9% Evista(R) 248.9 232.8 7% Strattera 119.8 141.1 (15)% Cymbalta 106.8 - N/M Alimta 93.9 … compared with the first quarter of 2004. Newer Products Strattera During the first quarter of 2005, Strattera, the …
Lilly Reports Third-Quarter 2011 Results
October 20, 2011 - … exchange rates. Revenue for Cymbalta, Humalog, Forteo, Strattera, Cialis and Alimta all grew in double-digits, with … many key brands, including Cymbalta, Humalog, Forteo and Strattera, with strong growth also seen in animal health, … the validity of the company's method-of-use patent on Strattera®. The method-of-use patent provides protection for …
Lilly Reports 7% Sales Growth, 10% Earnings Growth and $.80 EPS for Third Quarter
October 19, 2006 - … - Alimta(R), Byetta(R), Cialis(R), Cymbalta, Forteo(R), Strattera(R), Symbyax(R), Xigris(R) and Yentreve(R) - … (1)% 775.0 770.8 1% Alimta 157.2 122.3 29% 440.4 327.4 35% Strattera 126.4 140.9 (10)% 422.7 384.1 10% Forteo 149.1 … outside the U.S. increased 48 percent, to $67.3 million. Strattera Strattera sales were $126.4 million, a 10 percent …
Lilly Delivers 10 Percent Top Line Growth for Full Year 2004
January 26, 2005 - … products -- Alimta ® , Cialis ® , Cymbalta ® , Forteo ® , Strattera ® , Symbyax ? , Xigris ® and Yentreve ® -- … * Newer products -- Alimta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve -- contributed $1.548 … (5)% Gemzar(R) 329.5 282.6 17% Evista(R) 257.3 244.6 5% Strattera 183.4 132.6 38% Full Year % Change Over/(Under) …
Lilly Reports Second-Quarter EPS of $.76
July 21, 2006 - … -- Alimta ® , Byetta ® , Cialis ® , Cymbalta, Forteo ® , Strattera ® , Symbyax ® , Xigris ® and Yentreve ® -- … 543.7 268.2 103% Evista(R) 275.5 261.6 5% 517.0 510.5 1% Strattera 144.1 123.5 17% 296.4 243.2 22% Alimta 153.0 111.2 … and the unfavorable impact of foreign exchange rates. Strattera Strattera, the only nonstimulant medicine approved …